Ann: Regeneus signs MOU with Kyocera Corporation, page-14

Patent also covers Acute Respiratory Distress Syndrome

The patent to be granted for Progenza also covers Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition identified as a cause of death among patients diagnosed with COVID-19.

The success of Progenza on this front was recently documented in Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

ARDS is also a common cause of respiratory failure in critically ill patients.

Unlike pneumonia, there is no pharmaceutical treatment for ARDS23.

Notwithstanding the potential applications outside its core markets, Regeneus chief executive and executive director Leo Lee said, “While Regeneus’ focus remains on osteoarthritis and pain opportunities, this is a key patent which strengthens our intellectual property portfolio.

‘’It also opens doors to form partnerships for Progenza for other disease and indications.”

Anybody know anything about this???